Actively Recruiting
Phase 1b Open-Label Study of Multiple Doses of S-4321 by Injection in Adults With Autoimmune or Immune-Mediated Diseases Including RA, PsA, Psoriasis, CLE, or Atopic Dermatitis
Led by Seismic Therapeutic AU Pty Ltd · Updated on 2026-06-01
24
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating multiple doses of the drug S-4321 in adults aged 18 to 75 years who have various autoimmune or immune-mediated diseases. These conditions include rheumatoid arthritis, psoriatic arthritis, psoriasis, cutaneous lupus erythematosus with or without systemic symptoms, and atopic dermatitis. The study is an open-label Phase 1b basket trial designed to explore safety, how the drug behaves in the body, immune responses, biomarker changes, and early signs of effectiveness. Participants will receive multiple doses of S-4321 administered under the skin subcutaneous. The study is conducted across multiple centers and involves only the experimental drug without a placebo group. The treatment period and dosing schedule are designed to assess safety and biological effects over several weeks, with specific monitoring planned up to week 31. During the study, participants will undergo regular assessments including monitoring for treatment-related side effects and serious adverse events through week 31. Blood samples will be taken to measure drug levels, immune receptor activity, and the presence of antibodies against the drug. Disease activity and biomarker responses will also be evaluated. The trial is sponsored by Seismic Therapeutic AU Pty Ltd and aims to collect detailed safety and biological data over the treatment period.
CONDITIONS
Brief Title
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Research Team
S
Seismic Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here